Page last updated: 2024-11-09

n-(3,4-dimethoxyphenyl)-n-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-4-nitrobenzamide hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

BRL 32872: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID656770
CHEBI ID34551
MeSH IDM0248213

Synonyms (22)

Synonym
n-(3,4-dimethoxyphenyl)-n-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-4-nitrobenzamide monohydrochloride
unii-wfvi5d2fh4
wfvi5d2fh4 ,
n-(3,4-dimethoxyphenyl)-n-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-4-nitrobenzamide hydrochloride
113241-47-7
benzamide, n-(3,4-dimethoxyphenyl)-n-(3-((2-(3,4-dimethoxyphenyl)ethyl)methylamino)propyl)-4-nitro-, monohydrochloride
brl 32872
n-(3,4-dimethoxyphenyl)-n-[3-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amino]propyl]-4-nitro-benzamide
AC1LCVJH ,
CTK8G5946 ,
CHEBI:34551
surecn7333187
surecn678425
n-(3,4-dimethoxyphenyl)-n-(3-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}propyl)-4-nitrobenzamide hydrochloride (1:1)
DTXSID10150328
n-(3,4-dimethoxyphenyl)-n-[3-[2-(3,4-dimethoxyphenyl)ethyl-methylamino]propyl]-4-nitrobenzamide;hydrochloride
n-(3,4-dimethoxyphenyl)-n-[3-[2-(3,4-dimethoxyphenyl)ethyl-methyl-amin o]propyl]-4-nitro-benzamide h
brl-32872 free
n-(3-((3,4-dimethoxyphenethyl)(methyl)amino)propyl)-n-(3,4-dimethoxyphenyl)-4-nitrobenzamide hydrochloride
benzamide, n-(3,4-dimethoxyphenyl)-n-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-4-nitro-, hydrochloride (1:1)
brl-32872 hydrochloride
Q27116146

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"0 microM, the effect on APD was not further enhanced, and a bell-shaped dose-response curve resulted."( Electrophysiological effect of BRL-32872, a novel antiarrhythmic agent with potassium and calcium channel blocking properties, in guinea pig cardiac isolated preparations.
Bril, A; Cheval, B; Faivre, JF; Forest, MC; Gout, B; Linée, P; Poyser, RH; Ruffolo, RR, 1995
)
0.29
" New derivatives depicting bell-shaped dose-response curves on action potential duration may therefore represent novel agents for improved antiarrhythmic therapy."( Synthesis, electrophysiological properties and analysis of structural requirements of a novel class of antiarrhythmic agents with potassium and calcium channel blocking properties.
Bril, A; Cheval, B; Faivre, JF; Forest, MC; Gout, B; Martin, M; Nadler, G; Souchet, M, 1998
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's7 (70.00)18.2507
2000's3 (30.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.84 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.24 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]